Moderna’s COVID-19 vaccine candidate stimulated production of antibodies to the novel coronavirus in all of the patients tested in an early-stage study, and the company says the data support the selection of which dose to test in a pivotal clinical trial slated to begin at the end of July.
When the Cambridge, MA-based company initially reported unpublished data from the Phase 1 study in May, it could point only to preliminary results showing eight patients produced neutralizing antibodies—the type that protect against infection and lead to immunity. A more complete analysis of the study published in the New England Journal… Read more »
UNDERWRITERS AND PARTNERS
